{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:46:32Z","timestamp":1795095992497,"version":"4.10.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Amyloid cardiomyopathy (CA) was previously considered a rare disease; however, rapid advancements in imaging modalities have led to an increased frequency of its diagnosis. The aim of this prospective study was to assess the prevalence and clinical phenotype of transthyretin amyloidosis (ATTR) cardiomyopathy in patients exhibiting unexplained increased left ventricular (LV) wall thickness. From 2020 to 2022, we enrolled 100 consecutive adults with unexplained increased LV wall thickness in the study. The analysis included clinical data, electrocardiography, transthoracic echocardiography, single-photon emission computed tomography\/computed tomography with 3,3-disphono-1,2-propanodicarboxylic acid, genetic testing. Overall, 18% of patients were diagnosed with CA, comprising 5% with light-chain amyloidosis, and 12% with ATTR. To evaluate associations with the ATTR diagnosis, a LOGIT model and multivariate analysis were applied. Notably, age, polyneuropathy, gastropathy, carpal tunnel syndrome, lumbar spine stenosis, low voltage, ventricular arrhythmia, LV mass, LV ejection fraction, global longitudinal strain (GLS), E\/A, E\/E\u2032, right ventricle (RV) thickness, right atrium area, RV VTI, TAPSE, apical sparing, ground glass appearance of myocardium, thickening of interatrial septum, thickening of valves, and the \u201c5\u20135\u20135\u201d sign were found to be significantly associated with ATTR (p\u2009&lt;\u20090.05). The best predictive model for ATTR diagnoses exhibited an area under the curve of 0.99, including LV mass, GLS and RV thickness. This study, conducted at a cardiology referral center, revealed that a very considerable proportion of patients with unexplained increased LV wall thickness may suffer from underlying CA. Moreover, the presence of ATTR should be considered in patients with increased LV mass accompanied by reduced GLS and RV thickening.<\/jats:p>","DOI":"10.1007\/s10554-024-03158-z","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T08:01:45Z","timestamp":1718006505000},"page":"1693-1703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-4076","authenticated-orcid":false,"given":"Katarzyna","family":"Holcman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kostkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Szot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"\u0106miel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystian","family":"Mr\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"St\u0119pie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Graczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Dziewi\u0119cka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Karabinowska-Ma\u0142ocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Sachajko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Podolec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rubi\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"37","key":"3158_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al (2023) ESC Guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"key":"3158_CR2","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142:e558\u2013e631. https:\/\/doi.org\/10.1161\/CIR.0000000000000937","journal-title":"Circulation"},{"key":"3158_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506120500032196","volume":"12","author":"P Westermark","year":"2005","unstructured":"Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S et al (2005) Nomenclature committee of the international society of amyloidosis. Amyloid: toward terminology clarification. Report from the nomenclature committee of the international society of amyloidosis. Amyloid 12:1\u20134. https:\/\/doi.org\/10.1080\/13506120500032196","journal-title":"Amyloid"},{"key":"3158_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"3158_CR5","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA et al (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 26:2065\u20132123. https:\/\/doi.org\/10.1007\/s12350-019-01760-6","journal-title":"J Nucl Cardiol"},{"key":"3158_CR6","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 42:1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"3158_CR7","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"3158_CR8","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Casta\u00f1o","year":"2017","unstructured":"Casta\u00f1o A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A et al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38:2879\u20132887. https:\/\/doi.org\/10.1093\/eurheartj\/ehx350","journal-title":"Eur Heart J"},{"key":"3158_CR9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hag\u00e8ge AA, Donal E, Eicher JC, Slama M et al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37:1826\u20131834. https:\/\/doi.org\/10.1093\/eurheartj\/ehv583","journal-title":"Eur Heart J"},{"key":"3158_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.20452\/pamw.15140","volume":"130","author":"P Petkow-Dimitrow","year":"2020","unstructured":"Petkow-Dimitrow P, Rajtar-Salwa R, Holcman K, Kostkiewicz M, Rubi\u015b P (2020) From hypertrophic cardiomyopathy to transthyretin amyloidosis: an unusual case and challenging diagnosis. Pol Arch Intern Med 130:153\u2013154. https:\/\/doi.org\/10.20452\/pamw.15140","journal-title":"Pol Arch Intern Med"},{"key":"3158_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10554-016-1060-4","volume":"33","author":"E Merli","year":"2017","unstructured":"Merli E, Giudice ED, Antonopoulos A, Amadei G, Varani E (2017) Transthyretin cardiac amyloid and aortic stenosis in the elderly, the role of nuclear imaging. Int J Cardiovasc Imaging 33:947\u2013949. https:\/\/doi.org\/10.1007\/s10554-016-1060-4","journal-title":"Int J Cardiovasc Imaging"},{"key":"3158_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant\u00e9-Bordeneuve V, Lozeron P et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785\u2013792. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1","journal-title":"Neurology"},{"key":"3158_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"3158_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","volume":"4","author":"M Minamisawa","year":"2019","unstructured":"Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS et al (2019) Association of Patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study. JAMA Cardiol 4:466\u2013472. https:\/\/doi.org\/10.1001\/jamacardio.2019.0849","journal-title":"JAMA Cardiol"},{"key":"3158_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS et al (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139:431\u2013443. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035831","journal-title":"Circulation"},{"key":"3158_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"3158_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28:1-39.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003","journal-title":"J Am Soc Echocardiogr"},{"key":"3158_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovi\u0107 ZB, Hanna M, Plana JC et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442\u20131448. https:\/\/doi.org\/10.1136\/heartjnl-2012-302353","journal-title":"Heart"},{"key":"3158_CR19","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076\u20131084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073","journal-title":"J Am Coll Cardiol"},{"key":"3158_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583\u2013596. https:\/\/doi.org\/10.1056\/NEJMra023144","journal-title":"N Engl J Med"},{"key":"3158_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3109\/13506129.2013.825240","volume":"20","author":"T Damy","year":"2013","unstructured":"Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S et al (2013) Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 20:212\u2013220. https:\/\/doi.org\/10.3109\/13506129.2013.825240","journal-title":"Amyloid"},{"key":"3158_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytad200","author":"K Mr\u00f3z","year":"2023","unstructured":"Mr\u00f3z K, Rubi\u015b P, Podolec P, Kostkiewicz M, Holcman K (2023) Multimodality family screening of patients with cardiac transthyretin amyloidosis: a case of an asymptomatic patient. Eur Heart J Case Rep. https:\/\/doi.org\/10.1093\/ehjcr\/ytad200","journal-title":"Eur Heart J Case Rep"},{"key":"3158_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.5603\/CJ.a2020.0104","volume":"29","author":"M Gawor","year":"2022","unstructured":"Gawor M, Holcman K, Franaszczyk M, Lipowska M, Micha\u0142ek P, Teresi\u0144ska A et al (2022) Spectrum of transthyretin gene mutations and clinical characteristics of polish patients with cardiac transthyretin amyloidosis. Cardiol J 29:985\u2013993. https:\/\/doi.org\/10.5603\/CJ.a2020.0104","journal-title":"Cardiol J"},{"key":"3158_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"DR Jacobson","year":"1997","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med 336:466\u2013473. https:\/\/doi.org\/10.1056\/NEJM199702133360703","journal-title":"N Engl J Med"},{"key":"3158_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","volume":"43","author":"T Damy","year":"2019","unstructured":"Damy T, Kristen AV, Suhr OB, Maurer MS, Plant\u00e9-Bordeneuve V, Yu CR et al (2019) Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J 43:391\u2013400. https:\/\/doi.org\/10.1093\/eurheartj\/ehz173","journal-title":"Eur Heart J"},{"key":"3158_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.5603\/FC.2019.0115","volume":"14","author":"K Holcman","year":"2019","unstructured":"Holcman K, Kostkiewicz M, Podolec P, Rubi\u015b P (2019) Cardiac amyloidosis\u2014state-of-the-art diagnosis and emerging therapies. Folia Cardiol 14:616\u2013624. https:\/\/doi.org\/10.5603\/FC.2019.0115","journal-title":"Folia Cardiol"},{"key":"3158_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5603\/NMR.a2022.0033","volume":"25","author":"K Holcman","year":"2022","unstructured":"Holcman K, Dziuk M, Grzybowski J, Teresinska A, Malkowski B, Jedrzejuk D et al (2022) The scintigraphic diagnosis of cardiac amyloidosis. An expert opinion endorsed by the Section of nuclear medicine of the polish cardiac society and the polish nuclear medicine society. Nucl Med Rev Cent East Eur 25:142\u2013147. https:\/\/doi.org\/10.5603\/NMR.a2022.0033","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"3158_CR28","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM et al (2021) Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 6:1267\u20131274. https:\/\/doi.org\/10.1001\/jamacardio.2021.3070","journal-title":"JAMA Cardiol"},{"key":"3158_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J et al (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40:232\u2013239. https:\/\/doi.org\/10.1080\/07853890701842988","journal-title":"Ann Med"},{"key":"3158_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM et al (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2:113\u2013122. https:\/\/doi.org\/10.1016\/j.jchf.2013.11.004","journal-title":"JACC Heart Fail"},{"key":"3158_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/oxfordjournals.qjmed.a067513","volume":"46","author":"HM Hodkinson","year":"1977","unstructured":"Hodkinson HM, Pomerance A (1977) The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. Q J Med 46:381\u2013387. https:\/\/doi.org\/10.1093\/oxfordjournals.qjmed.a067513","journal-title":"Q J Med"},{"key":"3158_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0025-6196(12)64885-X","volume":"63","author":"JT Lie","year":"1988","unstructured":"Lie JT, Hammond PI (1988) Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 63:552\u2013564. https:\/\/doi.org\/10.1016\/S0025-6196(12)64885-X","journal-title":"Mayo Clin Proc"},{"key":"3158_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","volume":"270","author":"L Mohamed-Salem","year":"2018","unstructured":"Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, Hern\u00e1ndez-Vicente \u00c1, Reyes-Marle R, Castell\u00f3n S\u00e1nchez MI et al (2018) Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol 270:192\u2013196. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.006","journal-title":"Int J Cardiol"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-024-03158-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-024-03158-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-024-03158-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:24:01Z","timestamp":1726417441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-024-03158-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3158"],"URL":"https:\/\/doi.org\/10.1007\/s10554-024-03158-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3126241\/v1","asserted-by":"object"}]},"ISSN":["1875-8312"],"issn-type":[{"value":"1875-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}